

Medical Licensure

California Medical License #A133740 (active)

Commonwealth of Virginia #0101253339 (inactive)

| | |
|----------------------------------------------------------------------------------|------|
| Board Certification: Diplomate of the American Board of Psychiatry and Neurology | 2015 |
| Certification in the Subspecialty of Addiction Psychiatry, ABPN | 2016 |
| Certification in the Subspecialty of Addiction Medicine, ABPM | 2020 |
| Certification in the Subspecialty of Brain Injury Medicine, ABPN | 2020 |

DEA X Waiver

NPI# 1538459011

Graduate Medical Education

Fellowship: Addiction Psychiatry, UCLA-Kern July 2015–July 2016

Residency: Adult Psychiatry, VCU Medical Center July 2012–June 2015

Internship: Psychiatry, VCU Medical Center July 2011–June 2012

Education

Doctor of Medicine May 2010

American University of the Caribbean School of Medicine, St. Maarten

- *Phi Chi Medical Fraternity; Dean's Honor Society*

Bachelor of Science in Biology June 2006

University of California, Irvine, CA

- Golden Key Honor Society; Dean's Honor List

Professional Experience

Principal Investigator, SPRIM CRO August 2023-Present

Principal Investigator, CVS Health Clinical Trial Services June 2022-Present

Principal Research Investigator, Next Level July 2022-Present

CEO, The California Neuropsychiatric Institute November 2022-Present

CEO, Clinical Trial Link September 2021-Present

Venture Capitalist Advisor, Guidepoint August 2020-Present

Principal Research Investigator, Pacific Clinical Research Group September 2019-August 2022

Consultation and Liaison Psychiatrist, Arrowhead Hospital, San Bernardino September 2019-2022

Assistant Professor of Medicine, CUSM, San Bernardino April 2019-Present

| | |
|-------------------------------------------------------------------------|--------------------------|
| Faculty, Medical Education Speakers Network, Orange County | November 2018-Present |
| Assistant Professor of Psychiatry and Supportive Medicine, City of Hope | February 2017-April 2019 |
| Consultation and Liaison Psychiatrist, Kern Medical | July 2016-March 2017 |

Honors and Awards

| | |
|------------------------------------------------------------------------------------------------------------------|----------------|
| Teacher of the year California University of Sciences and Medicine | September 2021 |
| Excellence in Patient Care, Teaching, and Research UCLA-Kern, Bakersfield, CA | April 2017 |
| Fellow of the Year UCLA-Kern, Bakersfield, CA | April 2016 |
| Resident Poster Award IAPA Meeting, Toronto, Canada | May 2015 |
| Best Resident Poster Award Psychiatric Society of Virginia, Chantilly, VA | September 2014 |
| APA Research Colloquium for Junior Investigators Award American Psychiatric Association Meeting, New York, NY | May 2014 |

Teaching

| | |
|-----------------------------------------------------------------------------------------|-------------------------|
| Behavioral Medicine Pre-Clerkship Course director CUSM School of Medicine | April 2019-present |
| Co-director for the PGY-1 and PGY-2 didactic seminars Kern Medical Center | January 2016-March 2017 |
| Psychiatry Resident In-Training Examination Preparation VCU Department of Psychiatry | July 2014-June 2015 |

Pharmaceutical Clinical Trials Experience

Medical Director/Principal Investigator: Pacific Clinical Research Medical Center July 2018-2022

Principal Research Investigator on numerous phase II and III pharmaceutical sponsored clinical trials. Responsibilities include oversight of clinical trials, executing clinical protocols, ensuring data validity, monitoring for AEs and liaising with the sponsors.

General Medicine Experience

Assistant Professor of Medical Education: California University of Sciences April 2019-present

Diagnosed, assessed, and treated patients with general medical conditions in outpatient and inpatient settings. Common treated conditions include: hypertension, diabetes, high cholesterol, preventive medicine, vaccines, and health screenings. Developed teaching and research curricula for medical students and resident physicians.

Alzheimer's Disease Experience

Consultation and Liaison Psychiatrist: Arrowhead Regional Medical Center September 2019-present

Diagnosed, assessed, and developed treatment plans for patients with neurocognitive disorders admitted to the medical and surgical floors. Developed and implemented protocols to diagnose and treat patients presenting with symptoms of Alzheimer's dementia. Developed non-behavioral interventions to manage the cognitive and agitative sequelae.

PI Clinical Trial Experience

1. A Multicenter, Randomized, Flexible-dose, Double-blind Trial of Study Drug Versus Placebo for the Treatment of Adults With Borderline Personality Disorder Phase: II
2. A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Study Drug in the Treatment of Adult Subjects With Borderline Personality Disorder Phase: II
3. A Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of Study Drug as Adjunctive Treatment in Adults with Major Depressive Disorder with Anxious Distress with Suboptimal Response to Standard Antidepressants. Phase IIa
4. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Study Drug as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder Phase: III
5. A Double-Blind, Placebo-Controlled Study of Study Drug as an Adjunct to Antidepressants in the Treatment of Patients with Major Depressive Disorder who have had an Inadequate Response to Antidepressants Alone. Phase III
6. A Phase 3, Multicenter, Randomized, Double-blind Trial of Fixed-Dose Study Drug as Combination Therapy with Drug in the Treatment of Adults with Post-traumatic Stress Disorder Phase III
7. A Multi-center, Randomized, Controlled, 6-week Trial to Evaluate the Effectiveness of Device as Adjunctive Therapy in Adult Subjects Diagnosed with Major Depressive Disorder
8. A Randomized, Double-blind, Placebo-controlled Study of Study Drug for Relapse Prevention in Treatment Resistant Depression
9. A Double-Blind, Randomized, Parallel-Group Study with Drug as a Comparator to Evaluate the Efficacy and Safety of Study Drug 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
10. A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in Pediatric Participants (10 to 17 years of age) in the Treatment of Depressive Episodes Associated with Bipolar I Disorder Phase III.
11. A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral Study Drug Versus Placebo in Subjects With Major Depressive Disorder Phase IIa
12. A Multi-center, Randomized, Controlled, 6-week Trial to Evaluate the Effectiveness of Device as Adjunctive Therapy in Adult Subjects Diagnosed with Major Depressive Disorder
13. A Double-Blind, Placebo-Controlled Study of Study Drug as an Adjunct to Antidepressants in the Treatment of Patients with Major Depressive Disorder who have had an Inadequate Response to Antidepressants Alone Phase III
14. A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Study Drug in Obsessive Compulsive Disorder Phase III
15. A Multicenter, 48-week Open-Label Safety Study of Adjunctive Study Drug in Subjects with Obsessive Compulsive Disorder Phase III

16. A Phase 3, Multicenter, Randomized, Double-blind Trial of Fixed-Dose Study Drug as Combination Therapy with Drug in the Treatment of Adults with Post-traumatic Stress Disorder Phase III
17. A 26-week, Multicenter, Open-label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia or Bipolar I Disorder Phase III
18. Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of study drug for the treatment of migraine (with or without aura) in children and adolescents ≥ 6 to <18 years of age Phase III
19. A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Study Drug in Relapsing Multiple Sclerosis Phase II
20. REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial
21. A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) (RELIANCE-I)
22. A double-blind, randomized, placebo-controlled, parallel-group, fixed-dose, Phase 2 study of study drug as adjunctive therapy to antidepressant therapies (ADTs), for the treatment of subjects with generalized anxiety disorder (GAD) with inadequate response to ADT alone Phase II
23. A Phase III, multicenter, randomized, double-blind, controlled study to investigate the efficacy, safety and tolerability of COMP360 in participants with treatment-resistant depression
24. An Open-Label Study to Assess the Long-term Safety and Efficacy of Study Drug in Subjects with Treatment Resistant Depression
25. A Randomized, Double-blind, Placebo-controlled Study of Study Drug for Relapse Prevention in Treatment Resistant Depression
26. Study of a Respiratory Syncytial Virus mRNA Candidate With 2 Different Lipid Nanoparticle-based Formulations in Adults Aged 18 to 50 Years and 60 Years and Older
27. An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
28. Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures. Phase IV post marketing surveillance study.
29. Use of deep transcranial magnetic stimulation and a multidisciplinary biopsychosocial intervention to improve depression, comorbid anxiety, and pain in patients following autologous hematopoietic stem cell transplantation: A new approach to psychosocial distress in hematology. Phase II study
30. A Double-Blind, Randomized, Parallel-Group Study with Drug as a Comparator to Evaluate the Efficacy and Safety of Study Drug 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
31. A Study of Aticaprant as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy.

32. KAR-031/ A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimer's Disease Dementia
33. A Phase I/II, randomized, double-blind, placebo-controlled multi-arm dose-finding study to evaluate the safety and immunogenicity of a RSV mRNA vaccine candidate with either LNP CL-0059 or LNP CL-0137 in adult participants 60 years of age and older
34. IST-MC-AACI. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease, Phase III
35. A PHASE IV, OPEN-LABEL, DECENTRALIZED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF QELBREE® SPN-812 IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) AND MOOD SYMPTOMS

Presentations at National Meetings

Hassamal, S. Screening for Substance Use. Supportive Care Training Skills Symposium. City of Hope. Pasadena, CA, 2019.

Hassamal S. Addiction in Primary Care. Mental Health Symposium. City of Hope. Duarte, CA, 2018.

Hassamal S; Miotto K; Dale W; Danovitch, I. Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures. Central California Psychiatric Association Meeting. Yosemite, California, 2018.

Hassamal S; Haglund M; Wittnebel, K; Danovitch, I. A preoperative interdisciplinary opioid reduction program in patients on chronic opioid analgesia prior to spine surgery. American Psychiatric Association Meeting. Atlanta, Georgia, 2016.

Hassamal, S; Spivey, M; Fernandez, A; Pandurangi A. Augmentation therapy with serial intravenous ketamine over 18-months in a patient with treatment resistant depression: a case report and literature review. Indian American Psychiatric Association Meeting. Toronto, Canada, 2015.

Hassamal, S; Trutia, A; Dalkilic, A; Pandurangi, A. Body Image and Psychosis. American Psychiatric Association. New York, NY, 2014.

Hassamal S; Crouse-Breden E; Pandurangi, A. Suicide Trends in Virginia from 2003-2011. Psychiatric Society of Virginia. Portsmouth, VA, 2013.

Hassamal, S; Fernandez, A; Moradi Rekabdarkolae, H; Pandurangi, A. QTc prolongation in veterans with heroin dependence on methadone maintenance treatment. American Psychiatric Association. San Francisco, CA, 2013.

Intramural Presentations

Hassamal, S. Treating depression using Ketamine. Community Hospital of the Monterey Peninsula. CME presentation. 2022

Hassamal, S. Assessment and management of opioid use disorders. PIH Whittier. CME presentation. Whittier, CA. 2021.

Hassamal, S. Prescription Opioid Abuse: What Healthcare Professionals Need to know. Emanate Health Inter-Community Hospital. CME presentation. West Covina, CA, 2020.

Hassamal, S. Ketamine and other New Approaches to Treating Depression. West Hills Hospital & Medical Center. CME presentation. West Hills, CA, 2019.

Hassamal, S. Multimodal Pain Management. Lakewood Regional Medical Center. CME Presentation. Lakewood, CA, 2019.

Hassamal, S. Acute versus Chronic Pain Management. Northridge Hospital. CME Presentation. Northridge, CA, 2019.

Hassamal, S. Inpatient Pain Management. Los Robles Regional Medical Center. CME Presentation. Thousand Oaks, CA, 2018.

Hassamal, S. Diagnosis and Assessment of Prescription Opioid Use Disorders in Chronic Pain Populations. Pain Grand Rounds. City of Hope, Duarte, CA, 2018.

Hassamal, S. Chronic Benzodiazepine use and inpatient detoxification with Phenobarbital. Grand Rounds. Olive View-UCLA Medical Center. Olive View, CA. 2017.

Hassamal, S; Spivey, M; Pandurangi A. Augmentation therapy with serial intravenous ketamine over 18-months in a patient with treatment resistant depression: a case report and literature review. Grand Rounds. UCLA San Fernando Valley, North Hills, CA, 2016.

Hassamal, S; Trutia, A; Dalkilic, A; Pandurangi, A. Body Image and Psychosis. Grand Rounds. Virginia Commonwealth University, Richmond VA, 2015.

Hassamal, S and Baker, C. Sexualized Transference. Psychoanalytic Case Conference. Virginia Commonwealth University, Richmond, VA, 2014.

Hassamal, S and Bledowski, J. Adjunctive Aripiprazole Therapy in Alcohol Dependence. Inpatient Case Conference. Virginia Commonwealth University, Richmond, VA, 2013.

Hassamal, S and Zaller, E. A case of treatment resistant schizoaffective disorder. Inpatient Case Conference. Virginia Commonwealth University, Richmond, VA, 2012.

BIBLIOGRAPHY

Publications—Journals

Cohen, C.I., **S.K. Hassamal**, and N. Begum. General coping strategies and their impact on quality of life in older adults with schizophrenia. *Schizophr Res.* 2011. 127(1-3): p. 223-8. doi: 10.1016/j.schres.2010.12.023.

Hassamal S; Pandurangi A; Venkatachalam V; Levenson J. Delayed Onset and Prolonged ECT-Related Delirium. *Case Reports in Psychiatry.* 2013. doi: 10.1155/2013/840425.

Hassamal S; Fernandez A; Reabdarkolae H; Pandurangi, A. QTc prolongation veterans with heroin dependence on methadone maintenance treatment. *International Journal of High-Risk Behaviors and Addiction.* 2015. doi: 10.5812/ijhrba.4(2)2015.23819.

Shin S; **Hassamal S;** Peasley, L. Examining the Role of Psychological Distress in Linking Childhood Maltreatment and Alcohol Use in Young Adulthood. *American Journal of Addictions.* 2015. doi: 10.1111/ajad.12276.

- Hassamal, S**; Reese, K; Waller S; Testa, C. Reversible valproic acid-induced parkinsonism and cognitive impairment in an elderly patient with Bipolar Disorder I. *Turkish Journal of Psychiatry*. 2015. doi: 10.5080/u12251.
- Hassamal S**; Keyser-Marcus, L; Crouse-Breden E; Pandurangi, A. A brief analysis of suicide methods and trends in Virginia from 2003-2012. *BioMed Research International*. 2015. doi: 10.1155/2015/104036.
- Hassamal S**; Spivey M; Pandurangi A. Augmentation Therapy with Serial Intravenous Ketamine over 18-Months in a patient with Treatment Resistant Depression. *Clinical Neuropharmacology*. 2015. doi: 10.1097/WNF.000000000000104.
- Hassamal S**; Jolles, P; Pandurangi A. Reversal of Cerebral Glucose Hypometabolism on Positron Emission Tomography with Electroconvulsive Therapy in an Elderly Patient with a Psychotic episode. *Psychogeriatrics*. 2015. doi: 10.1111/psyg.12174.
- Hassamal S**; Goldenberg M; IsHak WW; Haglund M; Miotto K; Danovitch I. Overcoming Barriers to Initiating Medication Assisted Treatment for Heroin Use Disorder in a General Medical Hospital: a case report and narrative literature review. *J Psychiatr Pract*. 2017. doi: 10.1097/PRA.000000000000231.
- Goldenberg M; **Hassamal S**; IsHak WW; Miotto K; Haglund M; Danovitch I. A Call To Action: Psychiatry's Role in Managing the Growing Epidemic of Self-Medication with Drugs Acquired via the Internet. *The Journal of Clinical Psychiatry*. 2016. doi: 10.4088/JCP.15cr10606
- Hassamal S**; Haglund M; Wittnebel, K; Danovitch, I. A preoperative interdisciplinary opioid reduction program in patients on chronic opioid analgesia prior to spine surgery: a review of 5 cases. *Scandinavian Journal of Pain*. 2016. doi: 10.1016/j.sjpain.2016.06.007
- Hassamal S**; Wang T; Miotto K; Saxon, A. A narrative review: The effects of opioids on sleep disordered breathing in chronic pain patients and methadone maintained patients. *The American Journal on Addictions*. 2016. doi: 10.1111/ajad.12424.
- Hassamal S**; Trutia A; Dalkilic A; Pandurangi A. A pilot study of body image perceptions, and attitudes toward obesity in hospitalized psychotic and non-psychotic patients. *Asian Journal of Psychiatry*. doi:10.1016/j.ajp.2016.12.014.
- Mosher H, Herzig SJ, Danovitch I, Boutsicaris C, **Hassamal S**, Wittnebel K, Dashti A, Nuckols T. The Evaluation of Medical Inpatients Who Are Admitted on Long-term Opioid Therapy for Chronic Pain. *J Hosp Med*. 2017. doi: 10.12788/jhm.2889.
- Hassamal S**; Miotto K; Dale W; Danovitch, I. Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures. *The American Journal of Medicine*. 2018. doi: 10.1016/j.amjmed.2018.04.025.
- Hassamal S**; Razavi M; Clark K; Dale W; Loscalzo M. Pain Distress among Patients Prior to Initiating Cancer Treatment. *Journal of Psychoncology*. 2020. doi: <https://doi.org/10.1002/pon.5365>
- Hassamal S**, Dong F, Hassamal S, Lee C, Ogunyemi D, Neeki MM. The Psychological Impact of COVID-19 on Hospital Staff. *West J Emerg Med*. 2021 Feb 8;22(2):346-352. doi: 10.5811/westjem.2020.11.49015. PubMed PMID: 33856322; PubMed Central PMCID: PMC7972387.
- Serrano J, **Hassamal S**, Hassamal S, Dong F, Neeki M. Depression and anxiety prevalence in nursing staff during the COVID-19 pandemic. *Nurs Manage*. 2021 Jun 1;52(6):24-32. doi: 10.1097/01.NUMA.0000752784.86469.b9. PubMed PMID: 34016869; PubMed Central PMCID: PMC8162218.
- Hassamal S**. Chronic stress, neuroinflammation, and depression: An overview of pathophysiological mechanisms and emerging anti-inflammatories. *Front. Psychiatry*. 2023. doi: doi: 10.3389/fpsy.2023.1130989

Publications—Abstracts, Editorials, Book Chapters

Rahmani M, Abdullah C, Chandra P, **Hassamal S**, Cohen CI: Potential use of repetitive transcranial magnetic stimulation (rTMS) on cognitive functioning in patients with Alzheimer’s disease (abstract). American Journal of Geriatric Psychiatry 19(3) (suppl 1) S70, 2011.

Hassamal. S; Ramesh, D; Moeller, F.G. Resilience and Opiate Misuse. In The neurobiology of addiction (Eds). New York: Oxford University Press. 2015

Hassamal. S; Ramesh, D; Moeller, F.G. Pyromania. In Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, Tenth Edition (Eds). Philadelphia, PA: Wolters Kluwer, Lippincott Williams & Wilkins, 2015.

Hassamal. S; Ramesh, D; Moeller, F.G. Kleptomania. In Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, Tenth Edition (Eds). Philadelphia, PA: Wolters Kluwer, Lippincott Williams & Wilkins, 2015.

Ramesh, D; **Hassamal. S**; Moeller, F.G. Intermittent Explosive Disorder. In Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, Tenth Edition (Eds). Philadelphia, PA: Wolters Kluwer, Lippincott Williams & Wilkins, 2015.

Hassamal. S; Rzetelny A, Passik, S. Substance Use Disorders. In Psycho-oncology, Fourth Edition. Oxford Medicine. 2020

Hassamal, S. The Rise in Synthetic Cannabinoids and Cathinones. Psychiatric Times, Vol 38, Issue 7. July 13 2021.

Reviewer

Journal of Graduate Medical Education January 2020-Present

Leadership

Committee Member on Physician Wellbeing January 2020-Present
California Society of Addiction Medicine

Ethics Committee Member January 2020-Present
Arrowhead Medical Center

Psychiatry Residency Evaluation Committee Member September 2019-Present
Arrowhead Medical Center

College Faculty Mentor April 2019-Present
California University of Sciences and Medicine

Co-Editor of the ASAM Weekly August 2015-July 2016
American Society of Addiction Medicine

Administrative Chief Resident July 2013-June 2015
VCU, Department of Psychiatry

Professional Organizations

Association for Academic Psychiatry Member since 2020

California Society of Addiction Medicine Member since 2015

The American Academy of Addiction Psychiatry Member since 2015

American Psychiatric Association Member since 2012

